Article Text

Download PDFPDF
Sirukumab and adalimumab reduce power Doppler ultrasound signal in patients with rheumatoid arthritis by 4 weeks in a phase III trial

Statistics from Altmetric.com

Footnotes

  • Handling editor Josef S Smolen

  • Contributors All authors meet the journal’s criteria for authorship. All authors have contributed to the work and approve the presented findings.

  • Funding This study was funded by Janssen Research & Development.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Ethics approval The study protocols were reviewed and approved by an independent ethics committee or institutional review board for each study centre. This study is registered at EudraCT (number: 2013-001417-32) and ClinicalTrials.gov (number: NCT02019472).

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement All data are included in this letter and attached tables and figures.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.